In the May 25th issue, in the article "Possible Explanation for Failure of Bevacizumab and Sunitinib in Breast Cancer," several sentences about the actions of the Food and Drug Administration regarding bevacizumab (Avastin) were incorrect or unclear. The following is the correct information:

* Avastin is FDA approved for treatment of certain colon, lung, kidney, and brain cancers.

* FDA Commissioner Margaret Hamburg, MD, made the final decision in November to revoked the agency's earlier approval of the indication for metastatic breast cancer.

* All three breast cancer studies reviewed by the FDA met their primary endpoints for improving progression-free survival, but the indication was revoked, the agency stated, because it was believed that the benefits in breast cancer did not outweigh the risks.